Eton Pharmaceuticals, Inc. (ETON) · Aug 13, 2026 · Earnings
Beat — Revenue $37.6M vs ~$26.9M consensus; non-GAAP EPS $0.43 vs ~$0.15 consensus
Eton delivered a major Q2 beat and raised revenue and EBITDA guidance, with HEMANGEOL conversion and portfolio growth driving the upside.
The quarter was far ahead of the standing benchmark. Published estimates were roughly $26.9 million for revenue and $0.15 for EPS; Eton delivered $37.6 million of revenue and $0.43 of non-GAAP diluted EPS.
| Metric | Q2 2026 | Q2 2025 / expectation |
|---|---|---|
| Revenue | $37.6M (Net Revenue) | $18.9M prior year; ~$26.9M consensus |
| Revenue growth | 99% (Net Revenue) | — |
| GAAP diluted EPS | $0.35 (Net Income/Loss) | $(0.10) prior year |
| Non-GAAP diluted EPS | $0.43 (Net Income/Loss) | $0.03 prior year |
| Adjusted gross margin | 73% (Net Revenue) | 75% prior year |
| Adjusted G&A | $10.2M (R&D / G&A Expenses) | $7.6M prior year |
HEMANGEOL was the key surprise, not just an acquisition accounting boost. The product contributed new revenue after its May relaunch, while roughly 95% of existing patients had transitioned to Eton’s support program by the end of June. That conversion rate reduces the immediate execution risk around the relaunch and gives the company a stronger base for the second half. (HEMANGEOL relaunch section)
The guidance increase materially resets the year. Revenue guidance moved from more than $120 million to more than $145 million, while the minimum adjusted EBITDA margin rose from 30% to 35%. Management says the higher profitability target already absorbs the $3 million ASN-001 licensing expense, added development spending, and a potential $4 million ALKINDI milestone. (Guidance section)
The quality of growth is strong, though margins softened slightly. Adjusted gross margin declined to 73% from 75%, mainly because international INCRELEX sales carry negative gross margin. That is a genuine mix headwind, but it was outweighed by near-doubling revenue, a swing to GAAP profitability, and broad growth across the endocrinology and metabolic portfolio. (Net Revenue; Net Income/Loss)
The net read is a clear beat with more than one quarter of upside. HEMANGEOL’s contribution and the prior $120 million revenue guide were already partly known, so the novelty is primarily the magnitude of the launch performance and the new $145 million outlook. The filing also adds future optionality through ASN-001, KHINDIVI’s potential label expansion, AMGLIDIA, and the September IMPAVIDO launch, but those remain development or launch milestones rather than current revenue contributors. (HEMANGEOL relaunch; Guidance; IMPAVIDO; Development sections)
IMPAVIDO commercial launch, September 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!